Erectile dysfunction decisions — 2022

The Veteran's hypertension is granted as a presumptive condition caused by Agent Orange exposure. The service connection for erectile dysfunction, secondary to hypertension, is remanded.

The Veteran's lumbar DJD with IVDS and epilepsy were not rated higher than 40 percent, as there was no evidence of unfavorable ankylosis or incapacitating episodes. The Veteran’s bowel dysfunction and erectile dysfunction are separately rated.,Epilepsy was also not rated higher than 40 percent due to the lack of confirmed major seizures in the past year.

The Board has denied the Veteran's claim for service connection for Erectile Dysfunction (ED), finding that there is no evidence to support a causal or aggravating relationship between his ED and any of his service-connected disabilities, including his Type II Diabetes Mellitus.

The Board has remanded the cases for further development regarding potential exposure to herbicide agents during service in Panama. The Veteran's claims for various conditions are now pending.

The Board has granted service connection for erectile dysfunction as secondary to diabetes mellitus and remanded the issue of service connection for glaucoma.

The Board has dismissed all claims for service connection as the Veteran died after the appeal was remanded.

The Board has remanded several claims for further development, including obtaining VA treatment records and seeking additional medical opinions to address the etiology of various conditions. The claims include service connection for type 2 diabetes mellitus, hypertension, ankle disabilities, erectile dysfunction, and an acquired psychiatric disability.

The Veteran's claim for service connection for hypercholesterolemia is denied as it does not represent a disability in and of itself.,The Veteran's claims for increased ratings for lumbar strain with spondylosis prior to October 22, 2019 and hypertension are remanded due to inadequate examination and the need for additional medical opinions.,The Veteran's claim for service connection for a skin disability is remanded as there is insufficient evidence regarding its relationship to in-service events.,The Veteran's claims for service connection for diabetes mellitus, type II (DMII) and psychiatric disorder are remanded due to inadequate examination and the need for additional medical opinions.,The Veteran's claim for service connection for a cervical spine disability is remanded as there is insufficient evidence regarding its relationship to in-service events.,The Veteran's claims for service connection for sleep apnea and erectile dysfunction are remanded due to inadequate examination and the need for additional medical opinions.,The Veteran's claim for secondary service connection for erectile dysfunction as secondary to lumbar spine disability is remanded.

The Board denied the Veteran's claims for service connection for diabetes mellitus (type 1), peripheral neuropathy of the lower extremities, eye conditions, and erectile dysfunction as these conditions are not shown to be related to his military service.

The Veteran's claims for service connection for peripheral neuropathy of the bilateral upper and lower extremities, as well as his erectile dysfunction, are being remanded due to new evidence suggesting a possible relationship with his diabetes mellitus, type II.,The Veteran also has been diagnosed with peripheral neuropathy of the right and left upper and lower extremities. He claims these conditions are related to his service-connected diabetes mellitus, type II.

The Board has remanded the claims for prostate cancer and erectile dysfunction due to a lack of verification regarding herbicide/pesticide exposure during service. The Veteran's Social Security Administration benefits records must be obtained, and efforts should be made to verify any reported exposure to these agents.

The Board denied an initial rating higher than 20 percent for diabetes mellitus, type II, with erectile dysfunction, dermopathy, and retinopathy. The Veteran's diabetes was rated at 20 percent disabling under the old criteria due to restricted diet and oral hypoglycemic agent.

The claim for service connection of ED has been reopened and remanded due to the need for an examination to determine if ED was caused or aggravated by DMII.

The Board has decided to remand the cases for further examination and clarification of medical opinions regarding coronary artery disease and erectile dysfunction.

The Veteran's hypertension is granted as due to herbicide agent exposure. The claims for basal cell carcinoma, hypertension secondary to PTSD, erectile dysfunction secondary to PTSD, and sarcoidosis secondary to asthma/rhinitis are remanded.

The Veteran's claims for service connection on multiple conditions are being remanded due to the need for additional evidence and examination.

The Board denied readjudication of the service connection claims for bilateral hearing loss and tinnitus due to lack of new and relevant evidence. Service connection was granted for diabetes mellitus type 2, prostate cancer, chronic lymphocytic leukemia, and erectile dysfunction (ED) as secondary to prostate cancer.

The Board denied readjudication of the service connection claims for bilateral hearing loss and tinnitus due to lack of new and relevant evidence. Service connection was granted for diabetes mellitus type 2, prostate cancer, chronic lymphocytic leukemia, and erectile dysfunction (ED) as secondary to prostate cancer.

The Board denied readjudication of the service connection claims for bilateral hearing loss and tinnitus due to lack of new and relevant evidence. Service connection was granted for diabetes mellitus type 2, prostate cancer, chronic lymphocytic leukemia, and erectile dysfunction (ED) as secondary to prostate cancer.

The Board denied readjudication of the service connection claims for bilateral hearing loss and tinnitus due to lack of new and relevant evidence. Service connection was granted for diabetes mellitus type 2, prostate cancer, chronic lymphocytic leukemia, and erectile dysfunction (ED) as secondary to prostate cancer.